IARTIntegra LifeSciences Holdings Corporation
Is it safe?
Solid, nothing alarming: clean books, but big price swings.
Mixed, watch the balance sheet Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Reported earnings show no manipulation flags Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).
Mixed fundamental signals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -88% · now 32% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can IART take a bad year?
The deepest fall in IART's price history on file is −88%; it is 32% below its high today.
Net debt · as at Q2 2026 · debt less the cash on hand
- Altman Z-score
- 0.73
Altman Z-score · distress zone, below 1.8
- Interest cover
- 0.71×
Interest cover · operating profit does not cover the interest bill
- Annualised volatility
- 62%
Annualised volatility · three times the market's own swing
Details›
- Total debtQ2 2026
- $751M
- Cash and short-term investments
- $274M
- Net debt
- $477M
- Operating profit, trailing twelve months
- $66M
- Debt / equity
- 0.72×
- Annualised volatilitytwo years of daily moves
- 62%
- Worst drawdown on file
- −88%
- Below its 52-week high
- 32%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.